Sermorelin
Sermorelin Acetate
Sermorelin is one of the clearest legal alternatives in the peptide space and is commonly used when clinics want a compliant growth-hormone support option.
Current status
Legal
Growth-hormone-related interest, with current federal compounding constraints still in play.
FDA category
Category 1
Can pharmacies compound this?
Yes
Reclassification expected?
Unclear
Already functions as the contrast case for clinics that need a viable peptide today.
Primary Use
Growth-hormone-related interest
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Jul 1, 2025
Ingredient remained available through approved or established compounding pathways.
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Sermorelin status changes
State-specific notes
Tennessee
Often used as a substitute for restricted secretagogues.